• Read more about Jeff’s Weight Loss Surgery Success Story

When Jeff's weight started to impact his performances and his health, he turned to Cooper and a team who could help him succeed. Not only was Jeff’s weight affecting his performance, he was beginning to develop serious chronic illnesses

• Read more about ARTEMIDE 03

The purpose of this study is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a 1L treatment for patients with non-squamous mNSCLC whose tumors express PD-L1 (TC ≥ 1%).

Study Number:

ARTEMIDE 03/D702FC00001

Study Status:

Enrolling

Treatment Agent:

Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed

Resources and Links

National Clinical Trial Identified Number: NCT06627647

Disease:

• Non-Small Cell Lung Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Christian Squillante, MD

Department:

• Hematology and Medical Oncology

• Read more about ARTEMIDE-02

Short Title: ARTEMIDE-02

The purpose of the study is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line (1L) treatment for patients with squamous metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 (tumor cells (TC) ≥ 1%).

Study Number:

ARTEMIDE-02/D702BC00001

Study Status:

Enrolling

Treatment Agent:

Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel

Resources and Links

National Clinical Trial Identified Number: NCT06692738

Disease:

• Non-Small Lung Disease

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Christian Squillante, MD

Department:

• Hematology and Medical Oncology